231 related articles for article (PubMed ID: 19057212)
1. Perspective of Botox for treatment of male lower urinary tract symptoms.
Ilie CP; Chancellor MB
Curr Opin Urol; 2009 Jan; 19(1):20-5. PubMed ID: 19057212
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
3. Botulinum neurotoxin A for benign prostatic hyperplasia.
Oeconomou A; Madersbacher H
Curr Opin Urol; 2010 Jan; 20(1):28-36. PubMed ID: 19887944
[TBL] [Abstract][Full Text] [Related]
4. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
5. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
[TBL] [Abstract][Full Text] [Related]
6. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland.
Chuang YC; Huang CC; Kang HY; Chiang PH; Demiguel F; Yoshimura N; Chancellor MB
J Urol; 2006 Mar; 175(3 Pt 1):1158-63. PubMed ID: 16469644
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates.
Chuang YC; Chiang PH; Huang CC; Yoshimura N; Chancellor MB
Urology; 2005 Oct; 66(4):775-9. PubMed ID: 16230137
[TBL] [Abstract][Full Text] [Related]
8. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
9. Injectables in the prostate.
Saemi AM; Plante MK
Curr Opin Urol; 2008 Jan; 18(1):28-33. PubMed ID: 18090486
[TBL] [Abstract][Full Text] [Related]
10. Minimally invasive therapy of lower urinary tract symptoms.
Donnell RF
Urol Clin North Am; 2009 Nov; 36(4):497-509, vi-vii. PubMed ID: 19942048
[TBL] [Abstract][Full Text] [Related]
11. Prostatic tissue ablation by injection: a literature review.
Plante MK; Folsom JB; Zvara P
J Urol; 2004 Jul; 172(1):20-6. PubMed ID: 15201730
[TBL] [Abstract][Full Text] [Related]
12. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
13. Botulinum-A toxin: an exciting new treatment option for prostatic disease.
Thomas CA; Guercini F; Chuang YC; Chancellor MB
Int J Clin Pract Suppl; 2006 Dec; (151):33-7. PubMed ID: 17169009
[TBL] [Abstract][Full Text] [Related]
14. [Effects of intraprostatic injection of botulinum toxin A (BTX-A) on benign prostate hyperplasia].
Xu YP; Yu X; Ye ZQ; Pan TJ; Wen HD; Wang T
Zhonghua Nan Ke Xue; 2010 Oct; 16(10):905-10. PubMed ID: 21243754
[TBL] [Abstract][Full Text] [Related]
15. Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome.
Suardi N; Gallina A; Salonia A; Briganti A; Dehò F; Zanni G; Abdollah F; Naspro R; Cestari A; Guazzoni G; Rigatti P; Montorsi F
Curr Opin Urol; 2009 Jan; 19(1):38-43. PubMed ID: 19057214
[TBL] [Abstract][Full Text] [Related]
16. Treating benign prostatic hyperplasia with botulinum neurotoxin.
Brisinda G; Vanella S; Marniga G; Crocco A; Maria G
Curr Med Chem; 2011; 18(23):3468-75. PubMed ID: 21756236
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
19. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
Cruz F; Dinis P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):920-7. PubMed ID: 17705161
[TBL] [Abstract][Full Text] [Related]
20. Botox produces functional weakness in non-injected muscles adjacent to the target muscle.
Yaraskavitch M; Leonard T; Herzog W
J Biomech; 2008; 41(4):897-902. PubMed ID: 18184613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
